

To the kind attention of:

EudraCT team  
European Medicines Agency

**Subject:** End of Trial: prematurely ended due to futility

**TITLE: Efficacy and Safety of Dexmedetomidine during weaning from analgesia and sedation in Pediatric Intensive Care Unit. A multicenter, double-blind, randomized controlled trial.**

**UNIQUE PROTOCOL ID: EudraCT 2015-002124-80 OsSC**

**SECONDARY IDs: TIP-15-01**

**ETHICAL COMMITTEE APPROVAL NUMBER: CE 167/2016/O/Sper**

**SPONSOR: Azienda Ospedaliero-Universitaria di Bologna IRCCS Policlinico di Sant'Orsola**

**PRINCIPAL INVESTIGATOR: Maria Cristina Mondardini, MD - Azienda Ospedaliero-Universitaria di Bologna IRCCS Policlinico di Sant'Orsola, Pad 13 Via Albertoni 15 – 40138 Bologna, Italy. Phone: +390512143650. Email: [mariacristina.mondardini@aosp.bo.it](mailto:mariacristina.mondardini@aosp.bo.it)**

On 03/28/2020, after analyzing the interim analysis results, the study coordinator, in agreement with the Data and Safety Monitoring Board (DSMB), decided to prematurely interrupt the study. The decision to interrupt the study is due to futility.

The sample size calculation of the Trial was computed using an adaptive approach based on a two-stage Group Sequential Design with an interim sample size reassessment. After reaching the sample size for the interim analysis (i.e. n=40 patients enrolled who completed the study), the treatment efficacy was evaluated in the Intent-to-Treat (ITT) population using the Z test statistics in order to compare the prevalence of Withdrawal Syndrome (primary outcome measure) between the two treatment groups. The conditional power (CP) was found to be 0.25, i.e. lower than 0.3, which required a sample size reassessment. A sample size re-estimation assessment was equal to 308 patients. The DSMB was therefore consulted and a decision was made to early terminate the trial for futility reasons.

**Unità Operativa Anestesiologia e Rianimazione**  
**Direttore Dott. Fabio Caramelli**  
Via Massarenti, 13 - 40138 Bologna  
T. +39.051.214.4647 - F. +39.051.636.4321  
[anerialb@aosp.bo.it](mailto:anerialb@aosp.bo.it)

Study Start: August 30, 2018  
Primary Completion: January 18, 2020  
Study Completion: January 18, 2020

The Principal Investigator attaches the results of the interim analysis of the Trial published in the indexed journal *Pharmacotherapy*.



Maria Cristina Mondardini MD  
Principal Investigator

Bologna, 09/10/2022

**Unità Operativa Anestesiologia e Rianimazione**  
**Direttore Dott. Fabio Caramelli**  
Via Massarenti, 13 - 40138 Bologna  
T. +39.051.214.4647 - F. +39.051.636.4321  
anerianalb@aosp.bo.it

**Azienda Ospedaliero - Universitaria di Bologna**  
Via Albertoni, 15 - 40138 Bologna  
T. +39.051.214.1111 - F. +39.051.636.1202  
Cod. Fisc. 92038610371